A prodrug is a strategic innovation in biopharmaceutics designed to enhance the absorption, distribution, and delivery of therapeutic agents within the human body. This ingenious approach involves the administration of an inactive precursor that undergoes a biotransformation to the active drug form, either enzymatically or non-enzymatically, after administration.
In biopharmaceutics, prodrugs address challenges such as poor solubility, stability, or limited bioavailability of certain drugs. By converting the active compound into a prodrug, these limitations can be overcome, leading to improved therapeutic outcomes. Prodrugs also allow for targeted drug delivery, minimizing potential side effects and enhancing patient compliance.
The versatility of prodrugs spans various drug classes, including analgesics, antivirals, and anticancer agents. This approach exemplifies the continual evolution of pharmaceutical science in optimizing drug performance and patient well-being. As a key player in the realm of biopharmaceutics, prodrugs pave the way for more efficient and precise drug delivery strategies in the field of medicine.
Yong Xiao Wang
Albany Medical College, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Vladlen Slepak
University of Miami Miller School of Medicine, United States
Andreas M Papas
Antares Health Products, United States
Bernd Blobel
University of Regensburg, Germany
Huiqin Yang
ICON Clinical Research Ltd, United Kingdom
Srividya Narayanan
Northeastern University, United States
Maria Richards Brown
University College London, United Kingdom
Rassa Pegahi
UPSA, France
Hanieh Khalili
University of East London, United KingdomSubmit your abstract Today
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through design-inspired biotech- & biopharma-driven applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Genetic keys and nano locks: Unlocking personalized medicine
Srividya Narayanan, Northeastern University, United States
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad Autónoma de Baja California, Mexico